Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Advanced Solid Tumors and Metastatic Colorectal Cancer

Trial Profile

A Multi-Center, Open-Label, Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fruquintinib in Advanced Solid Tumors and Metastatic Colorectal Cancer

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Dec 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fruquintinib (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Hutchison MediPharma
  • Most Recent Events

    • 26 Nov 2019 Number of arms changed form 3 to 4, cohort B added having patients with metastatic colorectal cancer, Trial focus changed from AR to AR and TU. Planned patient number changed form 18 to 15
    • 26 Nov 2019 Planned End Date changed from 15 Dec 2019 to 15 Jun 2020.
    • 16 Nov 2018 According to a Chi-Med media release, this study is almost complete.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top